RESUMEN
Most, but not all, studies have found that women with a high urinary 2-hydroxyestrogen (2OHE) to 16alpha-hydroxyestrone (16alphaOHE1) ratio are at reduced risk for breast cancer and have a better prognosis. The aim was to identify factors associated with the pre-operative 2OHE to 16alphaOHE1 ratio and factors that predicted the change in the ratio between the pre-operative visit and first follow-up visit three to six months post-operatively among 59 women with primary ER positive breast cancer tumors. Body measurements, questionnaires and blood samples for measurements of the 2OHE and 16alphaOHE1 plasma levels and CYP1A2 *1F genotyping were collected at both visits. Post-operatively, 15 women received tamoxifen, 30 women tamoxifen and radiotherapy concomitantly, and 14 women radiotherapy. The pre-operative ratio was not correlated with tumor characteristics, but was significantly higher in women who consumed three or more cups of coffee daily (p = 0.009). The number of CYP1A2 *1F C-alleles was correlated with a lower ratio at both visits (p = 0.13 and p = 0.02, respectively). The ratio increased between the two visits in 69.5% of the women. The factors associated with a significant increase in the ratio were concomitant tamoxifen and radiotherapy (p = 0.006), increasing alcohol consumption (p = 0.006), and a high coffee consumption (p = 0.03), but not age or CYP1A2 *1F genotype. In this pilot study, breast cancer patients who started tamoxifen during radiotherapy and who had a moderate coffee and alcohol consumption demonstrated a significant improvement in their estrogen metabolite profile between the pre- and post-operative visits.
Asunto(s)
Consumo de Bebidas Alcohólicas , Neoplasias de la Mama/metabolismo , Café , Estrógenos/metabolismo , Hidroxiestronas/sangre , Hidroxitestosteronas/sangre , Adyuvantes Farmacéuticos , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/química , Neoplasias de la Mama/tratamiento farmacológico , Citocromo P-450 CYP1A2/genética , Antagonistas de Estrógenos/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Proyectos Piloto , Periodo Posoperatorio , Receptores de Estrógenos/análisis , Tamoxifeno/uso terapéuticoRESUMEN
Studies of circulating estrogen levels in relation to pre-menopausal breast cancer risk have yielded inconsistent results. Various estrogen metabolites might affect the risk differently. Estradiol metabolism occurs primarily via two mutually exclusive pathways, yielding 2-hydroxyestrone (2-OHE) and 16alpha-hydroxyestrone (16alpha-OHE). Most, but not all, studies have found that a relatively high 2-OHE/16alpha-OHE ratio is associated with a low breast cancer risk. Our objective was to determine if the 2-OHE/16alpha-OHE ratio in plasma correlates with suspected breast cancer risk factors and other lifestyle factors, such as ethnicity, body size, age at menarche, oral contraceptive use, smoking, vegetarian diet, coffee and alcohol consumption in 513 nulliparous women, aged 17-35. Oral contraceptive users had significantly lower 2-OHE/16alpha-OHE ratios than pill non-users (P = 10(-21)). Among women who were not using oral contraceptives, the median 2-OHE/16alpha-OHE ratio in plasma was similar for white, black, Indian/Pakistani and Asian women, after adjustment for age and menstrual cycle phase. Among oral contraceptive users, Asian women had significantly lower 2-OHE/16alpha-OHE ratios than white women, and this result remained after adjustment for age and day of menstrual cycle. Daily coffee consumption was significantly positively correlated with 2-OHE/16alpha-OHE ratios (r(s) = 0.18, P = 0.002) only among pill non-users. Our findings suggest that the plasma 2-OHE/16alpha-OHE ratio is associated with constitutional factors and with modifiable lifestyle factors. The reported elevated risk of early onset breast cancer among young oral contraceptive users could be mediated in part through altered estrogen metabolism induced by synthetic estrogens and progestins.
Asunto(s)
Neoplasias de la Mama/sangre , Neoplasias de la Mama/etnología , Etnicidad , Hidroxiestronas/sangre , Premenopausia , Administración Oral , Adolescente , Adulto , Población Negra , Anticonceptivos/efectos adversos , Terapia de Reemplazo de Estrógeno , Femenino , Humanos , Ciclo Menstrual , Paridad , Factores de Riesgo , Población BlancaRESUMEN
Alterations in the metabolism of estrogen have been implicated as an important factor in the etiology of diseases such as gynecological cancers and lupus erythematosus. The major metabolites of estradiol are hydroxylated at the C-2 or C-16 alpha position yielding products with estrogen antagonist and agonist activities, respectively. A sensitive and specific immunodiagnostic assay to determine the balance between these competing pathways might serve as a routine biomarker for management of estrogen-related diseases. We describe here the generation of high affinity, specific murine monoclonal antibodies to 2-hydroxyesterone and 16 alpha-hydroxyestrone by high efficiency fusion protocols. With these antibodies, we have developed a rapid and simple enzyme immunoassay (EIA) kit for the simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in unextracted urine. Initial validation studies established that urinary metabolite 2- and 16 alpha-hydroxyestrone concentrations found by the EIA correlate well with values found by gas chromatography-mass spectroscopy. Preliminary studies with the EIA kit found total recovery of metabolites from spiked urine samples. The EIA inter- and intra-assay coefficients of variation for 2-hydroxyestrone and 16 alpha-hydroxyestrone and the ratio of 2-hydroxyesterone to 16 alpha-hydroxyestrone with the current EIA kit were consistently less than 9%. This kit, designated ESTRAMET 2/16 may provide an important new tool for research in estrogen-related diseases.
Asunto(s)
Estrógenos de Catecol/orina , Hidroxiestronas/orina , Técnicas para Inmunoenzimas , Anticuerpos Monoclonales , Autoanálisis , Análisis Costo-Beneficio , Cromatografía de Gases y Espectrometría de Masas , Humanos , Técnicas para Inmunoenzimas/economía , Factores de TiempoRESUMEN
CA 125 has been extensively evaluated as a serum marker for monitoring patients with epithelial ovarian carcinoma. Recently, consideration has been given to the use of CA 125 as one component in a strategy for early detection of this disease. A number of benign conditions can, however, increase CA 125 in serum, limiting the utility of a single antigen determination for identifying ovarian cancer patients. Coexpression of different epitopes on the high molecular weight complexes that express CA 125 determinants might provide a more specific test for malignant disease, provided that adequate sensitivity were maintained. To determine how frequently determinants are coexpressed, macromolecular moieties containing CA 125 determinants have been isolated from ascites fluid of ovarian cancer patients by immunoaffinity chromatography. CA 125+ moieties have been probed on Western transfers with several murine monoclonal antibodies that recognize distinct tumor-associated epitopes. Marked heterogeneity was observed between patients with regard to antigenic determinants that could be coexpressed with CA 125. A fraction of ascites fluids from different ovarian cancer patients contained moieties which bound to OC 125 on a solid phase immmunoadsorbent and which also bound 125I-labeled monoclonal antibodies NS 19-9, B72.3, DF3, or the novel murine monoclonal antibody OC 3632 in a double determinant immunoradiometric assay. Serum samples were evaluated from patients with ovarian cancer and from apparently healthy individuals. Coexpression of TAG 72 and CA 125 was observed most frequently. When the double determinant assay for coexpression of TAG 72 and CA 125 was compared to assays for the individual antigens, the assay for coexpression was substantially less sensitive than those for the individual markers.
Asunto(s)
Anticuerpos Monoclonales , Antígenos de Carbohidratos Asociados a Tumores/inmunología , Epítopos/análisis , Neoplasias Ováricas/inmunología , Anticuerpos Monoclonales/aislamiento & purificación , Complejo Antígeno-Anticuerpo/análisis , Antígenos de Carbohidratos Asociados a Tumores/aislamiento & purificación , Ascitis/inmunología , Western Blotting , Línea Celular , Cromatografía Líquida de Alta Presión , Electroforesis en Gel de Poliacrilamida , Femenino , Humanos , Peso Molecular , RadioinmunoensayoRESUMEN
An immunoradiometric assay (IRMA) involving a monoclonal antibody (MAb OC125) to an ovarian carcinoma-associated antigenic determinant (CA 125) has been tested as one component in a strategy for early detection of epithelial ovarian cancer. We characterized one confirmed "false-positive" sample by murine antibody blocking studies, Western blotting, immunoaffinity, size-exclusion chromatography, and reactivity with polyclonal rabbit antisera to CA 125 antigen. The positive response of this serum in the CA 125 IRMA was due to a human IgM. The discrepant IgM was isolated from the serum by successive immunoaffinity steps with nonspecific murine MAb, MAb OC125, and goat antibodies to human IgM Fc. Purified IgM inhibited the binding of MAb OC125 to CA 125. Furthermore, rabbit antisera to CA 125 antigen competitively inhibited the binding of MAb OC125 to both CA 125 and the discrepant IgM. The discrepant activity thus appears to reflect binding of this human IgM to a idiotope of MAb OC125. Radioiodination of MAb OC125 by a different technique eliminated the discrepant activity and decreased the incidence of CA 125 positivity in an at-risk population of apparently healthy women, increasing the specificity of the IRMA to 99.8% in this group.
Asunto(s)
Anticuerpos Antiidiotipos/inmunología , Anticuerpos Monoclonales/inmunología , Antígenos de Neoplasias/análisis , Inmunoensayo , Idiotipos de Inmunoglobulinas/inmunología , Inmunoglobulina M/inmunología , Adulto , Animales , Antígenos de Neoplasias/inmunología , Antígenos de Superficie , Antígenos de Carbohidratos Asociados a Tumores , Cromatografía Líquida de Alta Presión , Epítopos , Reacciones Falso Positivas , Femenino , Humanos , Fragmentos Fab de Inmunoglobulinas , Inmunoglobulina G , Inmunoglobulina M/aislamiento & purificación , Radioisótopos de Yodo , Marcaje Isotópico , Ratones , Neoplasias Ováricas/inmunologíaRESUMEN
Monoclonal antibody 1116NS 19-9 (Mab 19-9) exhibits selective reactivity with human gastrointestinal carcinomas and recognizes a carbohydrate determinant (CA 19-9) defined as a sialylated lacto-N-fucopentaose II. A scheme was devised for the purification of a human gastrointestinal tumor-associated glycoprotein antigen expressing CA 19-9 from colorectal carcinoma cell line SW1116 culture media in high yield. The key steps in the purification were immunoaffinity column chromatography with Mab 19-9 followed by reduction and alkylation of the specifically bound proteins in the presence of 6 M guanidine hydrochloride and a second Mab 19-9 immunoaffinity fractionation. The purified CA 19-9 containing glycoprotein ran as a single band on sodium dodecyl sulfate-polyacrylamide gradient gels with an apparent molecular mass of 210 kilodaltons. In the absence of detergents, this purified glycoprotein apparently reassociated to form aggregates of 600-2000 kilodaltons molecular mass as determined by size-exclusion chromatography. Amino acid analysis of CA 19-9 containing glycoprotein revealed that serine, threonine, and proline together accounted for greater than 35% of the amino acid residues, consistent with a mucin-like structure for the protein. Carbohydrate compositional analysis, however, was in contrast to a typical mucin with a fucose:mannose:galactose:N-acetylgalactosamine: N-acetylglucosamine:N-acetylneuraminic acid molar ratio of 4:1:12:2.5:5:5. The presence of both N-acetylgalactosamine and mannose suggested that both O- and N-linked oligosaccharides may exist on CA 19-9 containing glycoprotein. Protein and carbohydrate analyses indicated that this novel tumor-associated glycoprotein was 85% carbohydrate by weight. This purification procedure may be applicable to the isolation of other epithelial tumor-associated antigens.
Asunto(s)
Antígenos de Neoplasias/aislamiento & purificación , Epítopos/aislamiento & purificación , Neoplasias Gastrointestinales/inmunología , Glicoproteínas/aislamiento & purificación , Aminoácidos/análisis , Anticuerpos Monoclonales/inmunología , Antígenos de Neoplasias/análisis , Antígenos de Carbohidratos Asociados a Tumores , Carbohidratos/análisis , Electroforesis en Gel de Poliacrilamida , Epítopos/análisis , Glicoproteínas/análisis , Humanos , Peso MolecularRESUMEN
The murine monoclonal antibody OC125 reacts with an antigenic determinant (CA 125) found on a high-molecular-weight glycoprotein complex present in the serum of greater than 80% of women with epithelial ovarian cancer. The antigen expressing CA 125 (CA 125 antigen) isolated from the sera of ovarian carcinoma patients was shown by gel electrophoresis, molecular size exclusion chromatography, and buoyant density ultracentrifugation to have similar immunological and physical characteristics to antigen isolated from an ovarian cancer cell line (OVCA 433) and human milk. A composite sodium dodecyl sulfate: polyacrylamide:1.0% agarose gel resolved the CA 125 activity from the three sources of antigen into disperse bands of similar electrophoretic mobilities with apparent masses of 200,000 to 1 million daltons. The buoyant densities of the CA 125 antigen complexes from human serum, OVCA 433 cells, and human milk were in the range of 1.36 to 1.46 g/ml. Isolation of CA 125 antigen of higher purity from OVCA 433 supernatant was achieved by a series of steps including OC125 immunoaffinity chromatography. Subsequent resolution of this purified CA 125 antigen complex by sodium dodecyl sulfate:polyacrylamide gel electrophoresis gave rise to a band at approximately 200,000 daltons. Treatment of the CA 125 antigen from OVCA 433 cells with 10 mM periodic acid resulted in no loss of activity. Reduction and alkylation in 6 M guanidine-HCl or treatment at 100 degrees C for 20 min resulted in complete loss of activity. Exoglycosidase treatments did not result in loss of activity, whereas protease digestion eradicated all activity. These data strongly suggest that the CA 125 antigenic determinant is composed of, at least in part, conformationally dependent peptide.
Asunto(s)
Antígenos de Neoplasias/aislamiento & purificación , Epítopos/análisis , Neoplasias Ováricas/inmunología , Antígenos de Neoplasias/análisis , Antígenos de Neoplasias/inmunología , Antígenos de Carbohidratos Asociados a Tumores , Carbohidratos/análisis , Cromatografía de Afinidad , Femenino , Glicósido Hidrolasas/farmacología , Humanos , Peso MolecularRESUMEN
CA 72 is a monoclonal antibody (MAb) -defined antigenic determinant expressed on a pancarcinoma antigen (TAG-72) found in more than 85% of human colorectal carcinomas. An immunoradiometric assay has been developed using the murine MAb B72.3 to quantitate CA 72 in human serum. In a simultaneous immunoradiometric assay, the mean CA 72 concentration in 1,099 serum samples from healthy blood donors was 1.83 +/- 2.03 (SD) units/ml. If the upper limit of normal was set at 10 mu/mol of serum, a value including 99% of healthy blood donors, only 4 of 101 serum samples (4%) from patients with benign disease were elevated, whereas 15 of 26 (58%) and 14 of 25 (56%) of rectal and colon carcinoma patient sera, respectively, were positive. Serum samples from 84 benign colorectal disease cases were examined; of these, 0 of 28 (0%) colorectal adenoma, 1 of 39 (3%) ulcerative proctocolitis, 0 of 15 (0%) diverticulosis, and 0 of 2 (0%) irritable bowel disease sera contained more than 10 mu/ml CA 72. At a reference value of 20 mu/ml, 0 of 101 (0%) benign disease and 2 of 1,060 (0.2%) blood donor sera had elevated values, whereas 10 of 26 (38%) and 9 of 25 (36%) rectal and colon patient sera, respectively, remained positive. The majority of patients with pancreatic and ovarian cancer, and a significant fraction of stomach cancer patient sera, also contained elevated levels of CA 72. The ability of this assay to discriminate between malignant and benign diseases suggests its further evaluation for monitoring and diagnosis in groups at risk for development of cancer.
Asunto(s)
Anticuerpos Monoclonales , Antígenos de Neoplasias/análisis , Epítopos/análisis , Glicoproteínas/análisis , Adulto , Factores de Edad , Análisis de Varianza , Antígenos de Carbohidratos Asociados a Tumores , Neoplasias del Colon/inmunología , Femenino , Enfermedades Gastrointestinales/inmunología , Humanos , Masculino , Persona de Mediana Edad , Radioinmunoensayo , Neoplasias del Recto/inmunología , Factores Sexuales , FumarRESUMEN
CA 19-9 and CA 125 serum levels were evaluated among smoking and nonsmoking healthy blood donors. Smoking did not elevate mean levels of either CA 19-9 or CA 125 in the sera of 496 of these blood donors from Philadelphia, PA. Mean CA 19-9 levels were slightly higher among females than among males. Among smokers there was a trend toward slightly increasing CA 19-9 serum levels with increased age, which was significant among the male donors. Trends toward slightly decreased mean serum levels of CA 125 among smokers were of borderline significance. Serum CA 19-9 and CA 125 levels in none of these donor subpopulations was elevated compared to levels reported by others for gastrointestinal or ovarian carcinoma patients, respectively. Therefore, smoking status should not interfere with use of either the CA 19-9 or CA 125 assays for diagnostic or monitoring applications.
Asunto(s)
Antígenos de Neoplasias/análisis , Fumar , Adulto , Factores de Edad , Antígenos de Carbohidratos Asociados a Tumores , Donantes de Sangre , Femenino , Humanos , Masculino , Factores SexualesRESUMEN
In a single fortuitous case it has been possible to measure serum levels of CA 125 during 3 years preceding the diagnosis of an epithelial ovarian carcinoma. CA 125 levels were elevated 10-12 months prior to clinical detection of the malignancy. CA 125 deserves further evaluation as a marker for early detection of ovarian cancer.
Asunto(s)
Antígenos de Neoplasias/análisis , Epítopos/análisis , Neoplasias Ováricas/inmunología , Agammaglobulinemia/inmunología , Antígenos de Carbohidratos Asociados a Tumores , Femenino , Humanos , Persona de Mediana Edad , Factores de TiempoRESUMEN
The human colorectal carcinoma cell line SW1116 under optimal growth conditions synthesized and shed antigens bearing the monoclonal antibody-defined carbohydrate determinant CA 19-9. Antigen expressing CA 19-9 in cell culture supernatant was quantitated by an immunoradiometric assay for CA 19-9. Injection of SW1116 cells s.c. into athymic BALB/c mice resulted in the growth of moderately differentiated tumors possessing a distinct morphological resemblance to a typical adenocarcinoma of the colon. Intervals to tumor appearance were dependent on inoculum dose, but 95% of mice at both 5 X 10(6) and 10(7) cells/mouse developed tumors within 14 to 21 days. CA 19-9 antigen was detected in the sera of all nude mice with SW1116 tumors, and antigen concentration correlated (r = 0.77) with tumor volume throughout the 9-week study. The half-life of this antigen in serum following tumor excision from nude mice was 6.5 +/- 1.5 (S.D.) hr. Carcinoembryonic antigen was also detected in serum from mice bearing SW1116 tumors by an immunoradiometric assay for carcinoembryonic antigen, but its concentration correlated (r = 0.86) with tumor volume for only the first 4 weeks of tumor growth. Significant levels of endogenous immunoglobulin G1 and immunoglobulin G3 antibodies to CA 19-9 antigen were found in the serum of nude mice with SW1116 tumors by radioimmunodiffusion, but no apparent relationship between antibody titer and tumor growth or CA 19-9 antigen level in serum was evident. This tumor model may be useful in devising radioimmunodetection and immunotherapeutic strategies for primary and metastatic human colon carcinomas.
Asunto(s)
Antígenos de Neoplasias/análisis , Neoplasias del Colon/inmunología , Epítopos/análisis , Animales , División Celular , Línea Celular , Neoplasias del Colon/patología , Citotoxicidad Inmunológica , Humanos , Cinética , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Trasplante HeterólogoRESUMEN
CA 125 and CA 19-9 are antigenic determinants associated with human epithelial ovarian carcinomas. Murine monoclonal antibodies have been raised against these determinants, and immunoradiometric assays have been developed to monitor antigen levels in the serum of cancer patients. This study was undertaken to determine whether concomitant measurement of CA 125, CA 19-9, and carcinoembryonic antigen would provide a more precise correlation with tumor progression or regression than could be obtained with any single assay. Among 105 patients with surgically demonstrable epithelial ovarian carcinoma, serum CA 125 levels were elevated (greater than 35 U/ml) in 83%, CA 19-9, levels (greater than 37 U/ml) in 17%, and carcinoembryonic antigen levels (greater than or equal to 2.5 ng/ml) in 37%. Within individual samples, no correlation was found among values for the three markers, but patients with elevated CA 19-9 levels also had increased levels of CA 125. At least one of the three markers was elevated in 90% of the subjects. When 41 patients were monitored serially over 2 to 60 months, alterations in CA 125 levels correlated with disease progression or regression in 94% of instances, whereas alterations in CA 19-9 levels correlated in 33% and alterations in carcinoembryonic antigen levels in 25% of instances. Concomitant measurement of CA 125, CA 19-9, and carcinoembryonic antigen did not prove superior to measurement of CA 125 alone in the monitoring of patients with epithelial ovarian carcinoma.
Asunto(s)
Antígenos de Neoplasias/análisis , Antígeno Carcinoembrionario/análisis , Epítopos/análisis , Neoplasias Ováricas/diagnóstico , Adenocarcinoma/diagnóstico , Adenocarcinoma Mucinoso/diagnóstico , Anticuerpos Monoclonales , Antígenos de Carbohidratos Asociados a Tumores , Carcinoma/diagnóstico , Cistadenocarcinoma/diagnóstico , Endometriosis/diagnóstico , Femenino , Humanos , Monitoreo Fisiológico , Radioinmunoensayo , Juego de Reactivos para Diagnóstico , Factores de TiempoRESUMEN
An immunoradiometric assay with the use of a monoclonal antibody can detect an antigenic determinant (CA125) in peripheral blood from more than 80% of patients with epithelial ovarian cancer. In this report elevated levels of CA125 were detected in serum from patients with adenocarcinomas of the fallopian tube, endometrium, and endocervix. Among patients with endometrial cancer, CA125 levels were elevated in recurrent or disseminated disease but not with tumors confined to the uterus.
Asunto(s)
Adenocarcinoma/diagnóstico , Antígenos de Neoplasias/análisis , Epítopos/análisis , Neoplasias de las Trompas Uterinas/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias Uterinas/diagnóstico , Anticuerpos Monoclonales , Antígenos de Carbohidratos Asociados a Tumores , Femenino , HumanosRESUMEN
CA 125 is an antigenic determinant expressed by greater than 80% of nonmucinous epithelial ovarian carcinomas. An immunoradiometric assay has been developed using a murine monoclonal antibody (OC125) to quantitate CA 125 in human serum. This immunoradiometric assay was optimized for specificity, sensitivity, and performance characteristics. Using a simultaneous immunoradiometric assay, the mean CA 125 concentration in 56 sera from healthy individuals was 11.2 +/- 5.4 (S.D.) units/ml, with 9.7 +/- 3.2 units/ml for 30 males and 13.1 +/- 6.8 units/ml for 26 females. A reference value of 35 units/ml included all 56 normals and excluded 86 of 105 (82%) ovarian carcinoma patients. This reference value also excluded 9 of 142 patients (6%) with benign diseases, but if the upper limit of normal was set at 65 units/ml, only 3 of 142 (2%) patients with benign diseases had elevated serum CA 125 levels, whereas 77 of 105 (73%) ovarian carcinoma patient sera remained positive. The ability of researchers, with this assay, to discriminate between CA 125 values in sera of patients with ovarian carcinoma and those of healthy individuals and patients with benign disease suggests that the assay deserves continued evaluation for monitoring and early diagnosis of ovarian cancer.
Asunto(s)
Anticuerpos Monoclonales , Carcinoma de Células Escamosas/inmunología , Epítopos/análisis , Neoplasias Ováricas/inmunología , Factores de Edad , Complejo Antígeno-Anticuerpo , Donantes de Sangre , Femenino , Enfermedades Gastrointestinales/inmunología , Humanos , Masculino , Radioinmunoensayo/métodos , Valores de Referencia , Factores SexualesRESUMEN
More than 1,600 coded sera obtained from blood donors and the NCI/Mayo Clinic Serum Bank were analyzed with an improved immunoradiometric assay for the carbohydrate antigenic determinant, CA 19-9. Results indicated that CA 19-9 is elevated in a large fraction of sera (67%) from patients with advanced adenocarcinomas of the upper gastrointestinal (GI) tract, including those with pancreatic, hepatobiliary and gastric carcinomas. Several of these sera had CA 19-9 exceeding 300,000 U/ml. A smaller fraction (18%) of patients with carcinomas of the large bowel had elevated serum CA 19-9 levels, the majority among patients with metastatic disease. In contrast, none of the healthy donors from the serum bank and only 4 of 1,023 of the blood donor specimens (0.4%) had CA 19-9 levels greater than or equal to 40 U/ml. Three of 235 sera (1.3%) from benign disease patients had levels of CA 19-9 in excess of 40 U/ml. These data suggest that the improved CA 19-9 immunoradiometric assay may have clinical utility as a diagnostic adjunct for adenocarcinoma of the upper GI tract and that the assay also may have some value in monitoring patients with advancing colorectal carcinoma, particularly in combination with CEA determinations. Rigorous prospective clinical trials will be necessary to verify these hypotheses.
Asunto(s)
Antígenos de Neoplasias/análisis , Carbohidratos/análisis , Epítopos/análisis , Neoplasias/inmunología , Adenocarcinoma/inmunología , Adenocarcinoma/terapia , Adulto , Anciano , Antígenos de Carbohidratos Asociados a Tumores , Antígeno Carcinoembrionario/análisis , Neoplasias del Colon/inmunología , Neoplasias del Colon/terapia , Femenino , Humanos , Técnicas Inmunológicas , Masculino , Persona de Mediana Edad , Neoplasias/terapia , Neoplasias Pancreáticas/inmunología , Neoplasias Pancreáticas/terapia , Radiometría , Neoplasias del Recto , Valores de Referencia , Neoplasias Gástricas/inmunología , Neoplasias Gástricas/terapiaRESUMEN
The murine monoclonal antibody OC 125 reacts with an antigen (CA 125) common to most nonmucinous epithelial ovarian carcinomas. An assay has been developed to detect CA 125 in serum. By this assay, only 1 per cent of 888 apparently healthy persons and 6 per cent of 143 patients with nonmalignant disease had serum CA 125 levels above 35 U per milliliter. In contrast, 83 of 101 patients (82 per cent) with surgically demonstrated ovarian carcinoma had elevated levels of antigen. In 38 patients with epithelial ovarian carcinoma monitored on 2 to 18 occasions during 2 to 60 months, antigen levels ranged from less than 1 to more than 8000 U per milliliter. Rising or falling levels of CA 125 correlated with progression or regression of disease in 42 of 45 instances (93 per cent). Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer.